Article Information
History
- July 14, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Alexander Neumann, PhD1,2,*,#,
- Fahri Küçükali, Msc1,2,
- Isabelle Bos, PhD3,
- Stephanie J.B. Vos, PhD4,
- Sebastiaan Engelborghs, PhD5,2,
- Tim De Pooter, BSc6,2,
- Geert Joris, BSc6,2,
- Peter De Rijk, PhD6,2,
- Ellen De Roeck, PhD7,2,
- Magda Tsolaki, MD, PhD8,
- Frans Verhey, PhD4,9,10,
- Pablo Martinez-Lage, MD11,
- Mikel Tainta, MD11,
- Giovanni Frisoni, PhD12,13,
- Oliver Blin, MD, PhD14,
- Jill Richardson, PhD15,
- Régis Bordet, PhD16,
- Philip Scheltens, MD17,
- Julius Popp, MD18,19,
- Gwendoline Peyratout, PhD20,
- Peter Johannsen, MD, PhD21,
- Lutz Frölich, MD, PhD22,
- Rik Vandenberghe, PhD23,
- Yvonne Freund-Levi, PhD24,25,
- Johannes Streffer, MD, PhD2,
- Simon Lovestone, PhD26,27,
- Cristina Legido-Quigley, PhD28,29,
- Mara ten Kate, PhD17,30,
- Frederik Barkhof, MD, PhD30,31,
- Mojca Strazisar, PhD6,2,
- Henrik Zetterberg, MD, PhD32,33,34,35,36,
- Lars Bertram, MD37,38,
- Pieter Jelle Visser, MD, PhD4,17,
- Christine van Broeckhoven, PhD39,2,
- Kristel Sleegers, MD, PhD1,2,
- EMIF-AD study group,
- Alzheimer’s Disease Neuroimaging Initiative*
- 1Complex Genetics of Alzheimer’s Disease Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
- 2Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- 3Netherlands Institute for Health Services Research, Utrecht, Netherlands
- 4Alzheimer Centrum Limburg, Maastricht University, Maastricht, Netherlands
- 5Department of Neurology and Memory Clinic, Universitair Ziekenhuis Brussel (UZ Brussel) and Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Brussels, Belgium
- 6Neuromics Support Facility, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
- 7Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium
- 81st Department of Neurology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Makedonia, Thessaloniki, Greece
- 9Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, Netherlands
- 10School for Mental Health and Neuroscience,, Maastricht University, Maastricht, Netherlands
- 11Center for Research and Advanced Therapies, CITA—Alzheimer Foundation, San Sebastian, Spain
- 12Department of Psychiatry, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland
- 13RCCS Instituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
- 14Clinical Pharmacology & Pharmacovigilance Department, Marseille University Hospital, Marseille, France
- 15Neurosciences Therapeutic Area, GlaxoSmithKline R&D, Stevanage, United Kingdom
- 16Neuroscience & Cognition, CHU de Lille, University of Lille, Inserm, France
- 17Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, Netherlands
- 18Department of Geriatric Psychiatry, University Hospital of Psychiatry Zürich, Zürich, Switzerland
- 19Old Age Psychiatry, Department of Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland
- 20Department of Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland
- 21Clinical Drug Development, Novo Nordisk, Copenhagen, Denmark
- 22Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
- 23Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium
- 24Center for Alzheimer Research, Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society Karolinska Institute Stockholm Sweden, Stockholm, Sweden
- 25School of Medical Sciences Örebro, University Örebro, Örebro, Sweden
- 26Department of Psychiatry, University of Oxford, Oxford, United Kingdom
- 27Janssen Medical Ltd, United Kingdom
- 28Steno Diabetes Center, Copenhagen, Denmark
- 29Institute of Pharmaceutical Sciences, King’s College London, London, United Kingdom
- 30Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, Netherlands
- 31Institutes of Neurology and Healthcare Engineering, University College London, London, United Kingdom
- 32Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden
- 33Department of Molecular Neuroscience,, UCL Institute of Neurology, London, United Kingdom
- 34Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
- 35UK Dementia Research Institute, University College London, London, United Kingdom
- 36Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China
- 37Lübeck Interdisciplinary Platform for Genome Analytics, University of Lübeck, Lübeck, Germany
- 38Centre for Lifespan Changes in Brain and Cognition, University of Oslo, Oslo, Norway
- 39Neurodegenerative Brain Diseases Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
- ↵#CORRESPONDING AUTHOR
Alexander Neumann, VIB Center for Molecular Neurology, Universiteitsplein 1, B-2610 Antwerp, Belgium, Email: alexander.neumann{at}uantwerpen.vib.be, Tel: +32 3 265 9830
Posted July 14, 2021.
Rare variants in IFFO1, DTNB and NLRC3 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation
